Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on August 10, 2021. The filing serves to announce the company's financial results for the three and six months ended June 30, 2021. The registrant is incorporated in California and its common stock is listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are detailed in the text of this filing. The document directs investors to the attached press release (Exhibit 99.1) for the announcement of results and any associated changes.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer regarding forward-looking statements (using terms like "may," "will," "believes," etc.). It warns that actual results may differ materially due to factors outlined in the company's Annual Report on Form 10-K under "Risk Factors."
- Legal Status of Information: Information in Item 2.02 and Exhibit 99.1 is deemed "furnished" and not "filed" under Section 18 of the Exchange Act, meaning it is not subject to the same liability standards as filed documents and will not be incorporated by reference into other filings unless expressly stated.
- Emerging Growth Company: The registrant has indicated it is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for actual financial figures (revenue, net loss, cash position) for the periods ended June 30, 2021.
- Verify the specific "Risk Factors" in the most recent Form 10-K to understand potential variances in forward-looking statements.
- Confirm the company's status as an emerging growth company and its election regarding accounting standard transition periods.
- Note that the financial data in this 8-K is "furnished" rather than "filed," which affects its legal incorporation into future SEC documents.